Mitochondrial medicine company NeuroVive Pharmaceutical AB (STO:NVP) reported on Tuesday loss before tax of SEK25,481,000, or SEK0.40 per diluted share, for the second quarter of 2018, from, April 2018 to June 2018.
This was a decline over loss before tax of SEK22,256,000, or SEK0,45 per diluted share, in q2 2017.
Net revenues for the quarter were nil, the same as in Q2 2017.
Other operating income for the quarter was SEK1,278,000, as compared with SEK88,000 in Q2 2017.
NeuroVive Pharmaceutical has one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases.
(EUR1.00=SEK10.53)
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government